1


                                                                   EXHIBIT 10.39





                                 PROMISSORY NOTE

PRINCIPAL $100,000.                                    ISSUE DATE: JULY 26, 2001

          1. PRINCIPAL AND INTEREST. Ampersand Medical Corporation, a
corporation organized and existing under the laws of the State of Delaware (the
"Company"), with offices at 414 N. Orleans St., Suite 510, Chicago, Illinois,
60610 for value received, hereby promises to pay to the order of Cadmus
Corporation (the "Holder"), with offices at 3600 Rio Vista Avenue, Suite A,
Orlando, Florida 32805, or any successor in interest, in lawful money of the
United States at the address of the Holder set forth above, the principal sum of
One Hundred Thousand and 00/100 Dollars ($100,000) on September 22, 2001 (the
"Maturity Date"), together with simple interest from the issue date above
identified (the "Issue Date"), computed on the basis of actual days elapsed over
a 365-day year from the date of original issuance until the Maturity Date, or
such earlier payment date as described below, at the rate of 15% per annum.

          2. PREPAYMENT. The principal amount of the Note, plus any accrued
interest due thereon, may be prepaid in its entirety at any time.

          3. ADDITIONAL CONSIDERATION. The Company hereby agrees to issue a
warrant in form and substance acceptable to the Holder, entitling the Holder to
purchase 250,000 shares of Common Stock of the Company at an exercise price of
$1.00 per share (the "New Cadmus Warrant"), within fifteen (15) days after the
Issue Date. If such warrant is not issued within such 15-day period, the
principal amount of this Note plus any accrued interest thereon shall be
immediately due and payable in its entirety and the Holder shall be entitled to
exercise such other rights and remedies as may be available to it at law or in
equity as a result of such default on the part of the Company. In addition, the
Company hereby agrees to issue to Azimuth Corporation ("Azimuth"), an affiliate
of the Holder, a warrant to purchase 500,000 shares of Common Stock of the
Company at an exercise price of $1.00 per share (the "New Azimuth Warrant") as a
replacement for the $1.00 conversion feature, which is a part of a convertible
Promissory Note, face value $500,000, issued by the Company on September 22,
2000, to Azimuth. Azimuth has agreed in writing to waive its conversion rights
under the aforementioned convertible Promissory Note coincidental with the
issuance of such warrant to purchase 500,000 shares of Common Stock of the
Company. The Company hereby agrees to include in the registration statement on
Form S-2 first filed by the Company with the Securities Exchange Commission on
July 17, 2001 all shares of Common Stock held by, or issuable upon exercise of
warrants (including the New Cadmus Warrant and New Azimuth Warrant) held by,
Cadmus, Azimuth, Winchester National, Inc., Alexander M. Milley or Robert C.
Shaw (the "Registrable Securities"). In addition, the Company agrees to execute
and deliver for the benefit of such persons and entities a registration rights
agreement, in form and substance satisfactory to such persons and entities, with
respect to such Registrable Securities. If such registration rights agreement is
not so executed and delivered within thirty (30) days after the Issue Date, the
principal amount of this Note plus any accrued interest thereon shall be
immediately due and payable in its entirety and the Holder (and such other
persons and entities) shall be entitled to exercise such other rights and
remedies as may be available to it at law or in equity as a result of such
default on the part of the Company.

          4. DEFAULT PENALTY PROVISIONS. If the Company fails to pay the
principal and accrued interest due thereon on the maturity date, interest shall
continue to accrue as computed above at an adjusted rate of 18% per annum from
the Maturity Date until the date the note and accrued interest is paid in full.

          5. RECLASSIFICATION, ETC. If the Company at any time shall, by
subdivision, combination or reclassification of securities or otherwise, change
any of the securities for which the warrants referred to herein are or will be
exercisable into the same or a different number of securities of any class or
classes of securities of the Company, or exchange any such securities in a
merger

   2

or acquisition for securities or property of another Company, the holders (or
prospective holders) thereof shall be entitled to the same rights in such new
securities or property as such holders would have been entitled to if
immediately prior to such change such holders had acquired shares of Common
Stock into which such warrants are or will be exercisable.

          6. USE OF PROCEEDS. The proceeds of the Note shall be used for general
corporate purposes.

          7. GOVERNING LAW. The Note is delivered in and shall be construed in
accordance with the laws of the State of Illinois, without regard to conflicts
of laws provisions thereof.

          IN WITNESS WHEREOF, and intending to be legally bound hereby, the
Company has caused this Note to be executed and delivered by its proper and duly
authorized officers as of the date first above written.

AMPERSAND MEDICAL CORPORATION


BY:
   --------------------------------
NAME:  LEONARD R. PRANGE
TITLE: PRESIDENT, COO/CFO